pre|CISIONTM drug conjugate (PDC)
The warhead is linked to a peptide specifically cleaved by fibroblast activation protein-α (FAP), thus releasing the warhead in the extracellular space of the TME.
The Avacta pre|CISIONTM platform is a proprietary warhead delivery system based on a tumour-specific protease that is designed to concentrate highly potent warheads in the tumour microenvironment while sparing normal tissues.
Fibroblast activation protein α (FAP) is an extracellular post-proline protease that is upregulated in many solid tumours in a membrane-bound form on cancer associated fibroblasts as well as tumour cells. FAP activity is also observed as a soluble protease to a low degree in plasma.
AVA6000 is the first clinical-stage pre|CISIONTM drug. It is a peptide drug conjugate that leverages the tumour-specific expression of FAP to target the release of doxorubicin to tumour tissue. It has two key properties:
- It prevents doxorubicin from entering cells.
- It is specifically cleaved by FAP to release active doxorubicin in the tumour.
Peptide Drug Conjugates – Multiple advantages over traditional ADC
pre|CISIONTM can be utilised in multiple drug formats:
pre|CISION drug conjugate (PDC)
The warhead is linked to a peptide specifically cleaved by fibroblast activation protein-α (FAP), thus releasing the warhead in the extracellular space of the TME.
Read morepre|CISION+ immuno-peptide drug conjugate
The peptide-warhead conjugate is linked to a biologic such as the Fc region, producing a pre|CISIONTM molecule protected from rapid clearance with warhead cleavage specifically enabled by FAP.
Read morepre|CISION ADC drug conjugate (AffDC)
The peptide-warhead conjugate is linked to a tumour antigen-targeted monoclonal antibody or Affimer® molecule, creating a highly tumour-specific ADC.
Read more